{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T18:45:11Z","timestamp":1771267511013,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003970","name":"Isfahan University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003970","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.msard.2021.103335","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T10:34:25Z","timestamp":1634639665000},"page":"103335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["COVID-19 infection and hospitalization rate in Iranian multiple sclerosis patients: What we know by May 2021"],"prefix":"10.1016","volume":"57","author":[{"given":"Saba","family":"Naghavi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aryan","family":"Kavosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iman","family":"Adibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vahid","family":"Shaygannejad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sina","family":"Arabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Rahimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahbanoo","family":"Mazaheri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fereshteh","family":"Ashtari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2021.103335_bib0004","unstructured":"National Multiple Sclerosis Society, 2021. What is MS. https:\/\/www.nationalmssociety.org\/What-is-MS\/Types-of-MS\/ (Accessed 19 Octobr 2021)."},{"key":"10.1016\/j.msard.2021.103335_bib0003","doi-asserted-by":"crossref","unstructured":"World Health Organization, 2020. news. https:\/\/www.who.int\/news\/item\/27-04-2020-who-timeline-covid-19\/ (accessed 27 April 2020).","DOI":"10.1097\/01.EEM.0000669380.03685.e2"},{"key":"10.1016\/j.msard.2021.103335_bib0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247461","article-title":"Population risk factors for severe disease and mortality in COVID-19: a global systematic review and meta-analysis","volume":"16","author":"Booth","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2021.103335_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.101967","article-title":"MS: immunosuppression is pass\u00e9","volume":"40","author":"Brod","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103335_bib0007","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41577-021-00522-1","article-title":"The first 12 months of COVID-19: a timeline of immunological insights","volume":"21","author":"Carvalho","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.msard.2021.103335_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.117147","article-title":"COVID-19 in multiple sclerosis patients and risk factors for severe infection","volume":"418","author":"Chaudhry","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2021.103335_bib0009","first-page":"68","article-title":"Review of the COVID-19 risk in multiple sclerosis","volume":"3","author":"Chaudhry","year":"2021","journal-title":"J. Cell. Immunol."},{"key":"10.1016\/j.msard.2021.103335_bib0010","doi-asserted-by":"crossref","first-page":"e1003","DOI":"10.1016\/S2214-109X(20)30264-3","article-title":"Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study","volume":"8","author":"Clark","year":"2020","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.msard.2021.103335_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102372","article-title":"Frequency and severity of COVID-19 in multiple sclerosis: a short single-site report from northern Italy","volume":"44","author":"Crescenzo","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103335_bib0012","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s12020-020-02364-8","article-title":"Thyroid disease in the time of COVID-19","volume":"68","author":"Dworakowska","year":"2020","journal-title":"Endocrine"},{"key":"10.1016\/j.msard.2021.103335_bib0013","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000787","article-title":"Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders","volume":"7","author":"Fan","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2021.103335_bib0014","doi-asserted-by":"crossref","first-page":"276","DOI":"10.12688\/wellcomeopenres.16349.1","article-title":"Impact of the first COVID-19 pandemic wave on the Scottish Multiple Sclerosis Register population","volume":"5","author":"Fernandes","year":"2020","journal-title":"Wellcome Open Res."},{"key":"10.1016\/j.msard.2021.103335_bib0015","doi-asserted-by":"crossref","first-page":"212","DOI":"10.15585\/mmwr.mm7006e2","article-title":"Decline in COVID-19 hospitalization growth rates associated with statewide mask mandates - 10 states, March-October 2020","volume":"70","author":"Joo","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.msard.2021.103335_bib0016","doi-asserted-by":"crossref","unstructured":"Khalagi K., Gharibzadeh S., Khalili D., et\u00a0al. Prevalence of COVID-19 in Iran: results of the first survey of the Iranian COVID-19 Serological Surveillance programme. Clin. Microbiol. Infect.2021. DOI: 10.1016\/j.cmi.2021.06.002.","DOI":"10.1016\/j.cmi.2021.06.002"},{"key":"10.1016\/j.msard.2021.103335_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.117230","article-title":"Immunosuppression in chronic autoimmune neurological disorders during the COVID-19 pandemic","volume":"420","author":"Kovvuru","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2021.103335_bib0018","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/acn3.51342","article-title":"Multiple sclerosis, rituximab, and COVID-19","volume":"8","author":"LangerGould","year":"2021","journal-title":"Ann\/ Clin\/ Transl\/ Neurol\/"},{"key":"10.1016\/j.msard.2021.103335_bib0019","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/jamaneurol.2020.2581","article-title":"Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis","volume":"77","author":"Louapre","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2021.103335_bib0020","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2021.103335_bib0021","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2021.103335_bib0022","doi-asserted-by":"crossref","DOI":"10.1111\/ene.14990","article-title":"Risk and outcomes of COVID-19 in patients with multiple sclerosis","author":"MorenoTorres","year":"2021","journal-title":"Eur. J. Neurol"},{"key":"10.1016\/j.msard.2021.103335_bib0023","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000835","article-title":"COVID-19 outcomes in MS: observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center","volume":"7","author":"Parrotta","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2021.103335_bib0024","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1038\/s41467-020-19741-6","article-title":"Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission","volume":"11","author":"Peckham","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.msard.2021.103335_bib0025","doi-asserted-by":"crossref","first-page":"e13916","DOI":"10.1111\/ijcp.13916","article-title":"Risk factors of the severity of COVID-19: a meta-analysis","volume":"75","author":"Rahman","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.msard.2021.103335_bib0026","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40263-021-00804-1","article-title":"COVID-19 in patients with multiple sclerosis: associations with disease-modifying therapies","volume":"35","author":"Reder","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2021.103335_bib0027","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0074-7742(07)79016-5","article-title":"Multiple sclerosis in Isfahan, Iran","volume":"79","author":"Saadatnia","year":"2007","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.msard.2021.103335_bib0028","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s12015-020-10094-7","article-title":"Dimethyl fumarate can enhance the potential therapeutic effects of epidermal neural crest stem cells in COVID-19 patients","volume":"17","author":"Safari","year":"2021","journal-title":"Stem cell Rev. Rep.s"},{"key":"10.1016\/j.msard.2021.103335_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102195","article-title":"B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran","volume":"43","author":"Safavi","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103335_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102472","article-title":"Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis","volume":"46","author":"Sahraian","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103335_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102193","article-title":"Knowledge regarding COVID-19 pandemic in patients with multiple sclerosis (MS): a report from Iran","volume":"42","author":"Sahraian","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103335_bib0032","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000954","article-title":"Incidence and impact of COVID-19 in MS: a survey from a Barcelona MS unit","volume":"8","author":"Sep\u00falveda","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2021.103335_bib0033","article-title":"COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: a systematic review","volume":"50","author":"SharifianDorche","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103335_bib0034","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1474-4422(20)30147-2","article-title":"An Italian programme for COVID-19 infection in multiple sclerosis","volume":"19","author":"Sormani","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2021.103335_bib0035","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ana.26028","article-title":"Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis","volume":"89","author":"Sormani","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2021.103335_bib0036","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","article-title":"Multiple sclerosis","volume":"391","author":"Thompson","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2021.103335_bib0037","doi-asserted-by":"crossref","DOI":"10.3390\/ph14010015","article-title":"Calming the (Cytokine) storm: dimethyl fumarate as a therapeutic candidate for COVID-19","volume":"14","author":"Timpani","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.msard.2021.103335_bib0038","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3389\/fendo.2020.00565","article-title":"Outcomes of patients with hypothyroidism and COVID-19: a retrospective cohort study","volume":"11","author":"van Gerwen","year":"2020","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.msard.2021.103335_bib0039","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2021.103335_bib0040","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.rdc.2015.08.004","article-title":"Infection risk and safety of corticosteroid use","volume":"42","author":"Youssef","year":"2016","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"10.1016\/j.msard.2021.103335_bib0001","unstructured":"Islamic Repablic News Agency, 2020, https:\/\/www.irna.ir\/photo\/84310879\/ (accessed 7 April 2020)."},{"key":"10.1016\/j.msard.2021.103335_bib0002","unstructured":"WorldOMeter, 2021. Coronavirus. https:\/\/www.worldometers.info\/coronavirus\/ (accessed 21 October 2021)."},{"key":"10.1016\/j.msard.2021.103335_bib0041","doi-asserted-by":"crossref","unstructured":"Zabalza A., C\u00e1rdenasRobledo S., Tagliani P., et\u00a0al. COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response. Eur. J. Neurol.2020. DOI:10.1111\/ene.14690.","DOI":"10.1111\/ene.14690"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821006027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821006027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T16:34:55Z","timestamp":1735576495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821006027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":41,"alternative-id":["S2211034821006027"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.103335","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19 infection and hospitalization rate in Iranian multiple sclerosis patients: What we know by May 2021","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.103335","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103335"}}